- Home
- NCRA vs LPCN Comparison
NCRA vs LPCN Comparison
Compare NCRA & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCRA
- LPCN
- Stock Information
- Founded
- NCRA 2002
- LPCN 1997
- Country
- NCRA Taiwan
- LPCN United States
- Employees
- NCRA N/A
- LPCN N/A
- Industry
- NCRA Farming/Seeds/Milling
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- NCRA Consumer Staples
- LPCN Health Care
- Exchange
- NCRA Nasdaq
- LPCN Nasdaq
- Market Cap
- NCRA 15.1M
- LPCN 16.1M
- IPO Year
- NCRA N/A
- LPCN N/A
- Fundamental
- Price
- NCRA $1.55
- LPCN $3.06
- Analyst Decision
- NCRA
- LPCN Strong Buy
- Analyst Count
- NCRA 0
- LPCN 2
- Target Price
- NCRA N/A
- LPCN $9.00
- AVG Volume (30 Days)
- NCRA 33.6K
- LPCN 20.2K
- Earning Date
- NCRA 08-14-2025
- LPCN 08-05-2025
- Dividend Yield
- NCRA N/A
- LPCN N/A
- EPS Growth
- NCRA N/A
- LPCN N/A
- EPS
- NCRA N/A
- LPCN N/A
- Revenue
- NCRA $13,865,984.00
- LPCN $4,208,119.00
- Revenue This Year
- NCRA N/A
- LPCN N/A
- Revenue Next Year
- NCRA N/A
- LPCN N/A
- P/E Ratio
- NCRA N/A
- LPCN N/A
- Revenue Growth
- NCRA N/A
- LPCN N/A
- 52 Week Low
- NCRA $0.70
- LPCN $2.68
- 52 Week High
- NCRA $2.09
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- NCRA 53.23
- LPCN 47.88
- Support Level
- NCRA $1.56
- LPCN $2.86
- Resistance Level
- NCRA $1.67
- LPCN $3.14
- Average True Range (ATR)
- NCRA 0.09
- LPCN 0.13
- MACD
- NCRA -0.03
- LPCN 0.00
- Stochastic Oscillator
- NCRA 33.22
- LPCN 50.76
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.